Contents
May 2017
Vol 2, Issue 11
Vol 2, Issue 11
Focus
- PD-1 and CTLA-4: Two checkpoints, one pathway?
PD-1–centered therapies rely on CD28 activation to promote anti-tumor immunity.
Research Articles
- The metabolic regulator mTORC1 controls terminal myeloid differentiation
The mTORC1-S6K1 pathway controls terminal differentiation of myeloid progenitors through regulation of Myc.
- Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells
Inactivated vaccinia virus induces antitumor immunity that can overcome resistance to checkpoint inhibitors.
- Targeting latency-associated peptide promotes antitumor immunity
Anti-LAP antibody induces antitumor immunity by affecting both adaptive and innate immune mechanisms.
- Virion incorporation of integrin α4β7 facilitates HIV-1 infection and intestinal homing
Anti–integrin α4β7 therapy might directly interfere with the ability of HIV to home to intestinal reserviors.
- Platelets subvert T cell immunity against cancer via GARP-TGFβ axis
T cell immunity against cancer in mice is enhanced with platelet-specific deletion of GARP and by platelet inhibitors.
- Ubiquitination of STING at lysine 224 controls IRF3 activation
The E3 ligase MUL1 regulates STING-dependent innate immune responses to cytosolic DNA.
Editors' Choice
- Beyond spell checking: Adding function to precision medicine
Immunoprofiling signaling pathways in rare immunodeficiencies aid design of targeted therapies.
- A Flicr of hope for autoimmunity
The long noncoding RNA Flicr modifies Foxp3 chromatin accessibility to reduce T regulatory cell differentiation and function.
About The Cover
ONLINE COVER Platelets Step Up Cancer Targets. Shown is an artistic representation of the cellular environment with two T cells (blue) attacking a tumor (pink) in the presence of platelets (gold). Rachidi et al. report that platelets constrain T cell immunity through a GARP-TGFβ axis and suggest a combination of immunotherapy and platelet inhibitors as a therapeutic strategy against cancer. [CREDIT: EMMA VOUGHT/MEDICAL UNIVERSITY OF SOUTH CAROLINA]
